Montelukast for the high impact of asthma exacerbations in Venezuela: a practical and valid approach for Latin America?

World Allergy Organization Journal

Dollys Hurtado²  Amaris Garcia³  Maria Gonzalez Yibirin¹  Arnaldo Capriles Hulett⁴ 

[1] LETI Laboratories, Caracas, Venezuela;Programa de Medicina Comunitaria, Centro Médico Docente, La Trinidad, Venezuela;General Practitioner, ambulatory health care facility “Los Erasos”; Health District 1, Ministry of Health, Caracas, Venezuela;Centro Médico de Caracas; Centro Médico Docente La Trinidad y Programa de Medicina Comunitaria; Allergology Unit, Hospital San, Juan de Dios, Caracas, Venezuela

关键词: Latin America;    Venezuela;    Deprived urban majorities;    Practical approach;    Montelukast;    Asthma control;    Asthma exacerbations;    Asthma;   

Others  :  1137622
DOI  :  10.1186/1939-4551-7-20

 received in 2013-09-10, accepted in 2014-07-10,  发布年份 2014

【 摘 要 】

Background

Asthma affects mainly Venezuela’s urban and poor majority. Exacerbations bring about a high demand in health services, thus becoming a significant public health problem. In general, asthma control programs (GINA) with use of inhaled steroid medications have proven effective, although their implementation in real life remains cumbersome. Montelukast could be a useful and practical tool for these deprived socioeconomic sectors.

Methods

This real-life pilot study was conducted in a prospective, double blinded, placebo-controlled manner with randomized and parallel groups. Asthmatics that had never used leukotriene modifiers were recruited and followed-up every three months. The main outcome was the number of exacerbations meriting use of nebulized bronchodilators administered by the health care system.

Results

Eighty-eight asthmatic patients were enrolled, between children and adults. Groups were comparable in: demographic data, previous use of other medications, ACT scores, pulmonary functions (Wright Peak Flow meter), allergy status (Skin Prick Test) as well as adherence to the prescribed Montelukast treatment. By an intention to treat (ITT), a total of 64 patients were included for analysis. For the three and six months time points the difference between placebo and Montelukast was found to be significant (p < 0.03 and p < 0.04, respectively). Such trends continued for the rest of the year, but without statistical significance, due to patient attrition.

Conclusions

This real-life pilot study shows that a simplified strategy with oral Montelukast was practical and effective in controlling exacerbations in an asthmatic population of a vulnerable community from Caracas. Such an approach reinforces the role of primary care in asthma treatment.

【 授权许可】

   
2014 Capriles Hulett et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Istúriz G, Guilarte A, Méndez R, España M: Norma Oficial Venezolana del Programa Nacional Integrado de Control del Asma. Publicación del MSAS, División de Tuberculosis y Enfermedades Pulmonares, patrocinado por el Programa de las Naciones Unidas para el Desarrollo; 1998.
• [2]Capriles Hulett A, Carvallo C, Sanchez A, Alfonzo I, Kondracki E: Revisión sobre el estado del asma infantil en Venezuela y una propuesta para su manejo. Revista de la Sociedad Venezolana de Alergia, Asma e Inmunologia 2004, VI(1):25-35.
• [3]Aldrey O, De Stefano M, Capriles-Hulett A: Prevalencia del asma infantil en Caracas, ISAAC 2003. Revista de la Sociedad Venezolana de Alergia, Asma e Inmunología 2003, V(No 2):33-40.
• [4]Mallol J, Sole D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C: Regional variation in asthma symptom prevalence in Latin American children. LatinAmerica ISAAC group J of Asthma 2010, 47(6):644-650.
• [5]Villamizar I, Garcia Lamogglia M, Meza J, Romero J: Generalidades. El asma como problema de salud publica. Definicion. Factores de riesgo. Fenotipos. Arch Venez Pueric Pediatr 2010, 73(2):48-54.
• [6]Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S: Global variation in the prevalence and severity of asthma symptoms: Phase III of ISAAC. Thorax 2009, 64:476-483.
• [7]España LP: 10 años detrás de la pobreza. Publicaciones UCAB 2010.
• [8]Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F: Asthma care in resource - poor settings. WAO J 2011, 4(4):68-72.
• [9]Hulett AC, Yibirin MG, Barreto RB, Garcia A, Hurtado D, Perez PA: Home/social environment and asthma profiles in a vulnerable community from Caracas: lessons for urban Venezuela. J Asthma 2013, 50(1):14-24.
• [10]Price D, Bosnic-Anticevivh BA, Chrystin H, Rand C, Scheuch G, Bousquet J: The inhaler error steering committee. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med 2013, 107:37-46.
• [11]Capriles A, Gonzalez M, Hurtado D: Symposium “Pitfalls of Allergic Diseases in Latin America”: Slum Asthma in Latin America, a Novel Approach. London: Handouts 29th Congress of EAACI; 2010. June 6th
• [12]Oral rehydration salts: Production of the new ORD. accesed febraury 2013 at whqlibdoc.who.inf
• [13]Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Phillip G: Effect of Montelukast for treatment of asthma in cigarette smokers. Allergy Clin Immunol 2013. Feb 1. Epub ahead of print
• [14]Cruz AA, Bateman ED, Bousquet J: The social determinants of asthma. Eur Resp J 2010, 35:239-242.
• [15]Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zachariasiewicz AS, Turener J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT: The effects of a monoclonal antibody directed against tumor necrosis factor - alpha in asthma. Am J Res Crit Care Med 2006, 174(7):753-762.
• [16]Unger A: Children’s health in slums settings. Arch Dis Child 2013, 98:799-805.
• [17]Graffar M: Une methode de classification sociale d’enchantillons de population. Courier 1956, 6(L):8. Septiembre 1956
• [18]Wright R, Suglia S, Levy J, Fortum K, Shields A, Subramaniam SV, Wright R: Transdisciplinary research strategies for understanding socially patterned disease: the Asthma Coalition on Community, Environment, and Social Stress (ACCESSS) project as a case study. Cien Saude Colet 2008, 13(6):1729-174.
• [19]Jackson D, Sykes A, Mallia P, Johnston S: Asthma exacerbations : origin, effect and prevention. J Allerg Clin Immunol 2011, 128(6):1165-1174.
• [20]PROVEA 2006: Informe anual. http://www.derechos.org.ve/pw/?attachment_id=1771 webcite. Derecho a la salud; accesed July 2014.
• [21]Hoyer and Clarembaux: Barrio adentro: historias de una misión. Coleccion Libros de EL NACIONAL 2009. ISBN:9789803884673
• [22]Souza-Machado C, Souza-Machado A, Franco R, Ponte EV, Barreto MC, Rodrigues LC, Bousquet J, Cruz AA: Rapid reduction in hospitalizations after an intervention to manage severe asthma. Eur Resp J 2010, 35(3):515-521.
• [23]Price D, Musgrave SD, Shepstone L, Hillyer EN, Sims EJ, Guilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, Wilson EC, Wolfe S, Freeman D, Mugford HM, Murdoch J, Harvey I: Leukotrienes antagonists as first - line or add - on asthma controller therapy. N Engl J Med 2011, 364(18):1695-1707.
• [24]Ducharme F, Noya FI, Allen-Rammey FC, Maisese EM, Gingres J, Blais L: Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Research Opinion 2012, 28(1):111-119.
• [25]Rodriguez E, Vera V, Perez-Puigbo A, Capriles-Hulett A, Ferro S, Manrique J, Abate J: A single dose of nebulized formoterol powder is as effective as three doses of albuterol in children’s acute asthma. Allergol Immunopathol (madr) 2008, 36(4):196-200.
• [26]Capriles E, Do Campo A, Verde O, Pluchino S, Capriles HA: Children’s asthma and the third world: an approach. J Investig Allergol Clin Immunol 2006, 16(1):11-18.
• [27]For information regarding phone services in Venezuela 2013. http://www.conatel.gob.ve webcite, telefonia movil, estadisticas. accesed July 2014
• [28]Petrie KJ, Perry K, Broadbent E, Weinman J: A text message programme designed to modify patient’s illness and treatment beliefs improves self-reported adherence to asthma preventer medication. Br J Health Psycholo 2012, 17:74-84.
• [29]Rule of two’s accessed at: http://www.dcasthma.org/rules_of_two_poster.pdf webcite. Is a federally registered trademark of Baylor Health Care system
• [30]Summary of Merck and Co. Inc. yahoo finance Accessed March 2013. biz.yahoo.com/e/…mlk10-qhtml
• [31]IMS’ XPLORA: Here the Reader can Find Data Regarding Actual Prices of Medications in Venezuela. Gaceta Oficial; 2014. Estimations in text were made according to the official rate of exchange (xls Sicad II. Banco Central de Venezuela at http://www.bcv.org.ve/c5/sicad/c9/tme01.asp webcite. Information concerning mínimum monthly wage can be found at: http://www.eluniversal.com/economia/140518/Venezuela-entre-los-paises-con-retraso-del-salariio-minimo webcite
• [32]Ponte EV, Franco R, Nascimento HF, Souza-Machado A, Cunha S, Barreto L, Naspitz C, Cruz AA: Lack of control of severe asthma is associated with co-existence of moderate-to severe rhinitis. Allergy 2008, 63:564.
• [33]Desler M®, 10 mgs tablets http://www.laboratorioslasante.com webcite